Gilead SciencesGILD
About: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Employees: 18,000
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
47% more first-time investments, than exits
New positions opened: 168 | Existing positions closed: 114
38% more funds holding in top 10
Funds holding in top 10: 13 [Q2] → 18 (+5) [Q3]
18% more capital invested
Capital invested by funds: $73.5B [Q2] → $86.5B (+$12.9B) [Q3]
2% more funds holding
Funds holding: 1,648 [Q2] → 1,682 (+34) [Q3]
3% more call options, than puts
Call options by funds: $965M | Put options by funds: $941M
10% less repeat investments, than reductions
Existing positions increased: 615 | Existing positions reduced: 683
2.42% less ownership
Funds ownership: 85.31% [Q2] → 82.89% (-2.42%) [Q3]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
10 analyst ratings
RBC Capital Brian Abrahams 16% 1-year accuracy 12 / 76 met price target | 13%downside $84 | Sector Perform Reiterated | 3 Feb 2025 |
JP Morgan Chris Schott 53% 1-year accuracy 9 / 17 met price target | 20%upside $115 | Overweight Maintained | 29 Jan 2025 |
Morgan Stanley Matthew Harrison 53% 1-year accuracy 10 / 19 met price target | 18%upside $113 | Overweight Upgraded | 10 Jan 2025 |
Cantor Fitzgerald Olivia Brayer 45% 1-year accuracy 10 / 22 met price target | 17%downside $80 | Neutral Reiterated | 11 Dec 2024 |
B of A Securities Tim Anderson 75% 1-year accuracy 6 / 8 met price target | 13%upside $109 | Buy Reinstated | 10 Dec 2024 |
Financial journalist opinion
Based on 37 articles about GILD published over the past 30 days









